How do I get Remicade through my insurance?
Remicade · infliximab · Reference product · provider-administered IV infliximab
No account, member ID, name, date of birth or email is needed. Your selections stay in this page session.
Make sure the authorization is for Remicade.
FDA’s Purple Book lists Remicade (infliximab) as the reference product under the 351(a) pathway and as a 100 mg single-dose vial for IV use. CMS describes HCPCS J1745 as infliximab excluding biosimilars, with each billing unit representing 10 mg. The treatment site can use J1745 as a checkpoint when comparing the medicine prescribed, authorized and billed. A billing code does not guarantee coverage.
- Do the prescription and authorization name Remicade?
- Does the plan’s current rule prefer another infliximab product?
- Is the infusion site named or restricted in the authorization?
- If a claim failed, do Remicade, the J1745 units, service date and site match the approval?
Want to compare the products? Review how Remicade, Inflectra, Avsola and Renflexis can differ in product preference, authorization and billing.
Check the coverage path for Remicade.
Choose the diagnosis and coverage type. The tool keeps Remicade selected while you check the plan source and product-preference detail.
Choose the diagnosis / reason.
The same infliximab product family can have very different medical-necessity requirements by diagnosis.
Match the approval to the planned infusion.
If another product is preferred
Ask the plan for the current rule and the reason Remicade was not approved. The prescriber and plan should determine whether an exception request or revised authorization is appropriate.
If an approved claim fails
Compare the authorization with the product billed, J1745 units, date, treatment location and provider on the claim before treating it as a new medical-necessity denial.
Find help with your out-of-pocket costs.
Use the official support program below to check savings, patient-assistance, or access options that may apply to you.
J&J withMe — Remicade →Questions about Remicade coverage.
Does an infliximab approval necessarily name Remicade?
Not necessarily. Ask the plan or authorization department to identify the exact product, code, site and date range approved.
What if the denial is only about product preference?
Ask for the current preferred-product rule and the requirements for Remicade. That is different from a finding that infliximab is not medically necessary.
Which billing code may appear on a Remicade claim?
CMS describes J1745 as infliximab excluding biosimilars, with each billing unit representing 10 mg. The treatment site should verify current payer and CMS coding before billing.
The medicine may be only part of the problem.
Use the playbook that matches what is blocking treatment, then verify the current rule with the insurer, program or treatment site.
Approval is pending, expired or unclear.
Find the rule, status and next authorization step.
DENIEDFind the reason before appealing.
Separate medical-necessity, benefit, product and claim problems.
PREFERRED PRODUCTThe plan wants a different brand or biosimilar.
Understand product preference without making a treatment recommendation.
SITE OF CAREThe medicine may be covered, but the location is not.
Check network, site and authorization requirements.
COST TOO HIGHSeparate coverage from financial assistance.
Understand manufacturer support versus independent foundations.
CLAIM PROBLEMAuthorization was approved, but billing still failed.
Compare the approval with the product, site and claim that were billed.
Important
MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. The member’s benefit plan, medical necessity, prior authorization, product preference, current billing code and site-of-care rules can change the outcome. Sources were reviewed 2026-10-08. Verify the current official source before acting.